ClinicalTrials.gg
RecruitingNCT07866066MARITIME-T2D-3Updated Nov 5, 2026

Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

A Phase 3 interventional study of Maridebart cafraglutide and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Amgen. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Now RecruitingFirst sites in Canada and United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetes Mellitus, Type 2 by Amgen — 3 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Amgen.

Planned enrollment
Largest of 16
1,300 · median 221
Started
2026
with 2 others
Phase 3
5 of 16
2 open now
Registered
16th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 2 by Amgen, this one has the largest planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 16 studies in Diabetes Mellitus, Type 2 by Amgen are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 2 by Amgen, or all of them as a file.
02

Study summary

The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Add-on to Metformin
  • Maridebart Cafraglutide
  • Semaglutide
  • MariTide
  • A1C
  • Weight
  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of ≥ 7.5% (58.0 millimoles per mole (mmol/mol)) and ≤ 10.5% (91.0 mmol/mol) at screening.
  • Treatment of Type 2 diabetes (T2D) with metformin (≥ 1500 milligrams per day (mg/day), or maximum tolerated dose as per investigator judgment) with or without an sodium-glucose cotransporter-2 (SGLT-2) inhibitor on a stable total daily dose for at least 90 days prior to randomization.
  • (BMI) ≥ 25 kilograms per meter squared (kg/m\^2) at screening.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes mellitus except T2D or past history of gestational diabetes.
  • Participants who are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
  • Participants who have a diagnosis of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy.
  • One or more episode of severe hypoglycemia (Level 3 hypoglycemia) within 180 days before screening, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery.
  • History of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
  • Self-reported change in body weight > 5% within 90 days before screening. Participants must also agree to not initiate an intensive diet or exercise program during the trial with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
  • Previous or planned (during the trial) surgical, endoscopic, or device-based treatment for obesity. The following are allowed:

    • liposuction and/or abdominoplasty that was performed > 1 year before screening.
    • laparoscopic adjustable gastric banding, intragastric balloon, and/or duodenal-jejunal bypass liner or gastric sleeve if removed > 1 year before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,300 participants (estimated)

Study arms

  • Experimental
    Maridebart cafraglutide

    Participants will receive maridebart cafraglutide administered subcutaneously (SC) once every 4 weeks (Q4W) in a dose-escalation manner.

    Drug: Maridebart cafraglutide

  • Active comparator
    Semaglutide

    Participants will receive semaglutide administered SC once weekly (QW) in a dose-escalation manner.

    Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c) at Week 68 [Non-inferiority]

    Time frame: Baseline to Week 68

Secondary outcomes

  1. Change from Baseline in HbA1c at week 68 [Superiority]

    Time frame: Baseline to Week 68

  2. Percent Change from Baseline in Body Weight at Week 68

    Time frame: Baseline to Week 68

  3. Percentage of Participants Achieving HbA1c < 7.0% at Week 68

    Time frame: Week 68

  4. Percentage of Participants Achieving HbA1c ≤ 6.5% at Week 68

    Time frame: Week 68

  5. Percentage of Participants Achieving HbA1c < 5.7% at Week 68

    Time frame: Week 68

  6. Change from Baseline in Fasting Plasma Glucose at Week 68

    Time frame: Baseline to Week 68

  7. Percentage of Participants Achieving ≥ 5% Reduction in Body Weight from Baseline at Week 68

    Time frame: Baseline to Week 68

  8. Percentage of Participants Achieving ≥ 10% Reduction in Body Weight from Baseline at Week 68

    Time frame: Baseline to Week 68

  9. Percentage of Participants Achieving ≥ 15% Reduction in Body Weight from Baseline at Week 68

    Time frame: Baseline to Week 68

  10. Percentage of Participants Achieving HbA1c ≤ 6.5% and Weight Reduction ≥ 10% from Baseline at Week 68

    Time frame: Baseline to Week 68

  11. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up To 81 Weeks

  12. Number of Participants Experiencing ≥ Level 2 American Diabetes Association (ADA) Defined Hypoglycemic Episodes

    Time frame: Up To 81 Weeks

  13. Plasma Concentration of Maridebart Cafraglutide at Week 68

    Time frame: Week 68

07

Study locations

8 of 8 sites recruiting
  • Acclaim Clinical Research
    San Diego, California 92120, United States
    Recruiting
  • Bioclinical Research Alliance
    Miami, Florida 33155, United States
    Recruiting
  • Indago Research and Health Center
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Clinical Research Center Of Florida
    Pompano Beach, Florida 33060, United States
    Recruiting
  • Conquest Research - Winter Park
    Winter Park, Florida 32789, United States
    Recruiting
  • Virginia Nephrology Group
    Arlington, Virginia 22205, United States
    Recruiting
  • Eastside Research Associates Health Research
    Redmond, Washington 98052, United States
    Recruiting
  • Dr T G Elliott Incorporated - BC Diabetes
    Vancouver, British Columbia V5Y 3W2, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 22 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 8, 2026
StartActual
Oct 16, 2026was Nov 2026
Primary completionEst.
Sep 6, 2028
CompletionEst.
Dec 5, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
8 sites added — first sites in Canada and United States
Show 8 added (7 United States, 1 Canada)
  • Acclaim Clinical Research · San Diego, United States
  • Bioclinical Research Alliance · Miami, United States
  • Indago Research and Health Center · Miami Lakes, United States
  • Clinical Research Center Of Florida · Pompano Beach, United States
  • Conquest Research - Winter Park · Winter Park, United States
  • Virginia Nephrology Group · Arlington, United States
  • Eastside Research Associates Health Research · Redmond, United States
  • Dr T G Elliott Incorporated - BC Diabetes · Vancouver, Canada
Nov 5, 2026
Start date
Nov 2, 2026→Oct 16, 2026 (actual)
Nov 5, 2026
Primary completion
Sep 4, 2028→Sep 6, 2028
Nov 5, 2026
Study completion
Dec 4, 2028→Dec 5, 2028
Nov 5, 2026
Registered
First appeared on the registry
Oct 8, 2026
Show all 2 updates
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    8 sites added — first sites in Canada and United States
    Show 8 added (7 United States, 1 Canada)
    • Acclaim Clinical Research · San Diego, United States
    • Bioclinical Research Alliance · Miami, United States
    • Indago Research and Health Center · Miami Lakes, United States
    • Clinical Research Center Of Florida · Pompano Beach, United States
    • Conquest Research - Winter Park · Winter Park, United States
    • Virginia Nephrology Group · Arlington, United States
    • Eastside Research Associates Health Research · Redmond, United States
    • Dr T G Elliott Incorporated - BC Diabetes · Vancouver, Canada
    Start date Nov 2, 2026→Oct 16, 2026 (now actual)
    Primary completion Sep 4, 2028→Sep 6, 2028
    Study completion Dec 4, 2028→Dec 5, 2028
    + 1 other change: verification date
  2. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07866066
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 8, 2026
Start date
Oct 16, 2026
Primary completion
Sep 6, 2028 (estimated)
Completion
Dec 5, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion